Mini-dose Dexmedetomidine-Esketamine Supplemented Analgesia in Patients at High-risk of OSA

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 11, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Obstructive Sleep ApneaSurgeryDexmedetomidineEsketaminePostoperative Sleep Quality
Interventions
DRUG

Dexmedetomidine-esketamine combination

Patient-controlled analgesia is established with dexmedetomidine (1 μg/ml), esketamine (1 mg/ml), and sufentanil (1 μg/ml) in a total volume of 100 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours after surgery.

DRUG

Placebo

Patient-controlled analgesia is established with sufentanil (1 μg/ml) in a total volume of 100 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours after surgery.

Trial Locations (1)

100034

RECRUITING

Peking University First Hospital, Beijing

All Listed Sponsors
lead

Peking University First Hospital

OTHER